Zevalin market set for growth as lymphoma cases rise
The Business Research Company says the Zevalin market is expanding on the back of rising non-Hodgkin lymphoma cases, aging populations and broader healthcare infrastructure. North America led the market in 2025, while the report forecasts growing adoption of targeted radioimmunotherapy through 2026 and beyond.
Why it matters: - Zevalin’s market potential is tied to rising demand for targeted cancer treatments with lower toxicity. - Growth in non-Hodgkin lymphoma cases and aging populations could expand the patient pool for radioimmunotherapy. - Healthcare systems with stronger nuclear medicine and oncology infrastructure are better positioned to adopt Zevalin.
What happened: - The Business Research Company released a Zevalin market report covering market size, trends and a global forecast through 2026-2035. - The report says North America held the largest share of the Zevalin market in 2025 and is expected to remain the leading region through 2026. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - More information is available in the full report and a free sample.
The details: - Zevalin, or ibritumomab tiuxetan, is a monoclonal antibody drug used to treat non-Hodgkin lymphoma. - The therapy combines an antibody with yttrium-90 to deliver targeted radiation to cancer cells. - The report says Zevalin can help slow lymphoma progression while sparing healthy tissue. - Market growth has historically been supported by monoclonal antibody advances, improvements in nuclear medicine, better non-Hodgkin lymphoma detection, early adoption of radiolabeled therapies and oncology imaging progress. - Future growth is expected to benefit from investment in targeted cancer treatments, demand for personalized medicine, expanded radiopharmaceutical infrastructure, lower-toxicity treatment goals and antibody-therapy innovation. - The report highlights broader adoption of targeted radioimmunotherapy, precision oncology, lymphoma-focused protocols, improved nuclear medicine integration and more selective treatment approaches as key trends. - Non-Hodgkin lymphoma remains a major demand driver because Zevalin targets CD20 on affected B-cells. - The American Cancer Society projected about 80,620 new U.S. non-Hodgkin lymphoma cases in 2024, including 44,590 in men and 36,030 in women. - The American Health Care Association reported in May 2023 that the U.S. hospital count rose to 6,129 from 6,093 a year earlier. - The UK House of Commons Library reported in July 2024 that people aged 65 and older made up about 19% of the UK population in 2022, with that share projected to reach 27% by 2072.
Between the lines: - The report frames Zevalin as a niche but potentially more relevant therapy as oncology shifts toward precision medicine and targeted delivery. - North America’s lead suggests stronger reimbursement, infrastructure and treatment adoption than in other regions. - The market outlook also reflects a broader oncology trend: therapies that improve efficacy without adding toxicity are gaining strategic importance.
What's next: - The report expects continued expansion in targeted radioimmunotherapy and precision oncology through the forecast period. - More healthcare infrastructure buildout could widen access to Zevalin and similar therapies in emerging markets. - The company says the 2026 report includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics, key technology analysis and updated graphics and tables.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Culture Zone! UK
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.